Severe suppression of the hematopoietic system is a major factor in limiting chemotherapy dose escalation. To determine whether a combination of human recombinant granulocyte colony-stimulating factor (G-CSF) and thrombopoietin (TPO) would alter recovery of platelets, red blood cells (RBCs), or neutrophils after myeloablative therapy, myelosuppressed mice were treated with sc injections of TPO (90 pg/kg), G-CSF (250 pg/kg), TPO plus G-CSF or vehicle and complete blood counts were measured. Marrow and spleen cells were obtained at various times and assayed for erythroid, myeloid, and megakaryocytic progenitors. The prolonged neutropenia in vehicle controls (14 days) was significantly shortened in mice treated with G-CSF or TPO for 14 HE DEPLETION of hematopoietic precursors in the T bone marrow (BM) associated with chemotherapy and irradiation result in hemorrhagic and infectious complications. A number of hematopoietic cytokines are currently in use or in clinical trials as treatments to prevent or reduce such complications. Thrombopoietin (TPO)'-3 (also termed mpl-ligand: thrombopoietic f a~t o r ,~ or megapoietid), stimulates megakaryocyte colony formation and increase the size, ploidy, and differentiation markers of megakaryocytic cells in vitro. In contrast, granulocyte colony-stimulating factor (G-CSF) primarily promotes the proliferation and differentiation of neutrophil progenitors and aids in the release of neutrophils from the BM.'-"
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In normal animals, both TPO and G-CSF exhibit lineage specific effects on peripheral blood cell counts. TPO exclusively increases platelet and G-CSF increases only neutrophil However, in myelosuppressed animals, TPO not only reduces the time to platelet recovery, but also shortens the time to red blood cell (RBC) and neutrophil re~overy.'~ Recent studies have shown that TPO increases the number of myeloid, erythroid, and megakaryocytic progenitors both in vitro and in vivo~~3~14~15~20-zz The mechanism for the enhanced neutrophil and erythrocyte recovery is believed to be a direct effect of TPO on hematopoietic stem and progenitor cells, working in concert with additional endogenous cytokines released in response to the myelosuppressive treatment.
G-CSF primarily affects the recovery of neutrophils but has also been shown to enhance RBC and platelet recovery in myelosuppressed mice.23 Because G-CSF, like TPO, is thought to act both early and late in hematopoiesis, we hypothesized that the combined effects of both cytokines might further enhance hematopoietic recovery in myelosuppressed animals. This is clinically relevant, since many myelosuppressed patients who would be candidates for TPO treatment already receive G-CSF to shorten neutrophil recovery times.
To explore the interactions between these two cytokines we treated myelosuppressed mice with either TPO alone, G-CSF alone, or with TPO plus G-CSF, and evaluated the effects on peripheral blood cells and on progenitor cells in BM and spleen. Our results show that mice treated with TPO plus G-CSF have earlier neutrophil recovery than mice treated with G-CSF or TPO alone, as well as more rapid recovery of erythropoiesis and thrombopoiesis. These results suggest that the combined use of the cytokines may further reduce the pancytopenia associated with intensive chemotherapy.
MATERIALS AND METHODS
Mice. Eight-to 9-week-old female Balbk mice were obtained from Jackson Laboratories (Bar Harbor, ME). Mice were acclimated for at least 2 weeks after arrival before the start of the experiments and were housed at ZymoGenetics (an AAALAC-accredited facility) under specific pathogen-free conditions. Mice were housed in microisolator cages (5 micekage) in rooms which operated on a 12 hour light-dark cycle. Acidified water and irradiated standard laboratory rodent chow (LM-485; Harlan Teklad, Madison, WI) were supplied ad libitum. After irradiation, the cages containing the myelosuppressed mice were kept on circulating water heating pads. All animal experiments were reviewed and approved by the ZymoGenetics Animal Care and Use Committee.
The myelosuppressive regimen was similar to that of Leonard et aIz4; however, a more radiosensitive mouse strain was used in combination with lower doses of radiation to reduce general toxicity. On day 0, mice were exposed to 350 cGy total body irradiation from a 137Cs source (Gammacell 40 Irradiator, Nordion Intemational, Inc, Kanata, Canada), immediately followed by an intraperitoneal injection of 1. 
~~ ~~
Oaks, CA) was used at 250 pgkgld in the vehicle consisting of acetate (0.59 mg), mannitol (50.0 mg), Polysorbate 80 (0.004%), and sodium (0.035 mg) with water for injection. Two experiments were performed and pooled to study the effect of TPO treatment on blood parameters. Each treatment group consisted of 10 mice which were treated with cytokines for 14 days. To evaluate the effects of TPO and/or G-CSF on the numbers of progenitor cells and on BM morphology, additional groups of mice were treated on an identical protocol until 24 hours before sacrifice on days 9 or 13. Recombinant human TPO was expressed in mammalian cells.2s TPO was captured and eluted from a mimetic green dye affinity column. The eluate from this column was then further purified by anion exchange chromatography and hydroxyapatite chromatography. Purified TPO migrated on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gels at a molecular weight of approximately 70 kD, essentially free of contaminating proteins. Protein concentrations determined by amino acid analysis and biological activity were assessed by the in vitro mitogenesis assay using BAF-3 cells engineered to express the human c-mpl receptor.' The quantity of TPO required to induce half maximal proliferation of BAF-3/h-mpl cells was 0.19 ? 0.03 ng/mL. Endotoxin levels were 5 . 6 EU/dose. G-CSF (Neupogen) was purchased from Amgen.
Peripheral blood (PB) (60 pL) was collected (under ether anesthesia) from the retroorbital sinus in heparinized capillary tubes and immediately transferred to EDTA coated microtainer tubes (Becton Dickinson [BD], San Jose, CA). Complete blood counts and differentials were performed on 50 pL blood with an Abbott Cell-Dyn 3500 hematology analyzer (Abbott Diagnostics, Santa Clara, CA) using mouse discriminator settings. Baseline values were collected for each mouse 5 to 7 days before irradiatiordchemotherapy treatment and are shown on the graphs as day 0.
Reticulocytes were measured on a FACScan flow cytometer (BD). One microliter of blood was stained for 30 minutes at room temperature in the dark with Retic-Count (BD) according to the manufacturer's instructions. Unstained and stained cells were analyzed for each sample. Cells that were positive in the unstained sample were subtracted from the positive cells of the sample stained with thiazole orange. Results are reported as calculated reticulocyte indices.
The sternum from each mouse was fixed in 10% neutral buffered formalin and decalcified in 20% sodium acetate and 10% formic acid. Paraplast X-TRA embedded specimens were longitudinally sectioned at 3 pm and stained with hematoxylin and eosin for light microscopic examination. The number of megakaryocytes was counted in each sternum under high power (40X objective) and the number of megakaryocytes/mm2 was calculated. To describe the percent of nucleated cells and neutrophils in the marrow, 200 cells were randomly counted from each marrow section. The percentage of BM cellularity was measured in three fields at randomly chosen segments of each sternum by using a light microscope ( l o x objective, Olympus, BH-2) interfaced to a BioScan Optimas image analysis system (Optimas Corporation, Bothell, WA). Simultaneously, the data was computed and stored. Data analysis are performed by using ANOVA followed by Bonferroni Multiple Comparisons Test.
Single cell suspensions of spleen cells and flushed femur BM cells were plated at a density of 1.5 X lo5 cells per plate (15 x 10 mm culture plates, Nunc, Naperville, IL) in 0.3% agar with 750 UlmL TPO for determination of CFU-Meg, or with TPO plus 10 ng/mL recombinant murine stem cell factor (SCF; Genzyme, Cambridge, MA) and 100 U/mL murine GM-CSF (Sigma, St Louis, MO) for determination of myeloid progenitors colony-forming unit granulocyte macrophage (CFU-GM). Colonies were counted 6 days after plating for CFU-GM, and 13 days after Recombinant human TPO (TPO) and G-CSF.
Hematological evaluation.
Reticulocyte counts.
Histology.

Colony forming assays.
plating for CFU-Meg. In addition, single cell suspensions were plated at a density of 1 X lo6 per plate in 3% methylcellulose with 2 U/mL erythropoietin (EPO; Amgen), 10 ng/mL SCF. and 100 U/mL granulocyte-macrophage CSF (GM-CSF) for determination of CFU-granulocyte-erythroid-macrophage-megakaryocyte (CFU-GEMM) and burst-forming unit erythroid (BFU-E). Colonies were counted 14 days after plating. Colonies were defined as clusters of >40 cells, except for CFU-Meg, which were counted as clusters of two or more cells. Standard morphologic criteria were used to distinguish CFU. All plates were counted without knowledge of the treatment received by the donor mouse.
The effects of treatment on various parameters were analyzed using either the nonparametric Kruskal-Wallis Test followed by Dunn's Multiple Comparison Test or ANOVA followed by Bonferroni Multiple Comparisons Test. Analyses that yielded a P-value of P < .05 were considered significant. Analyses were performed using Instat (Graphpad Software, San Diego, CA).
Statistical analysis.
RESULTS
Effect of TPO and G-CSF treatment on PB cell recovey.
Radiatiodcarboplatin treatment produced a severe reversible thrombocytopenia, anemia, and neutropenia. Neutrophil counts were reduced to 6.3% of baseline and stayed at low levels for at least 2 weeks (Fig 1A) . Platelet counts were reduced to 6.2% of pretreatment values in vehicle controls by day 9, stayed at reduced levels for a week and then retumed to normal values by day 23 (Fig 1B) . Vehicle controls also showed progressive anemia. Red blood cell counts were lowest on day 20 (35.5% of baseline) and recovered to near normal values by day 30 (Fig 1C) .
The time required to retum to 50% of baseline neutrophil counts was significantly shortened in TPO plus G-CSF treated mice compared to mice treated with either TPO or G-CSF alone ( P < .001) and was 15 days earlier than vehicle controls (Fig lA, Table 1 ). Mice treated with TPO or G-CSF alone recovered 6 or 10 days earlier compared to vehicle controls (Table 1) . To determine whether TPO plus G-CSF treatment altered the neutrophil nadir, the lowest neutrophil count was determined for each mouse. Nadir neutrophil counts were similar in the vehicle, G-CSF and G-CSF plus TPO groups but were higher in mice treated with TPO alone ( Table 2) .
Platelet counts of mice treated with G-CSF or TPO alone or TPO plus G-CSF recovered to 50% of baseline significantly faster than controls ( Table 1) . Mice treated with TPO or TPO plus G-CSF showed significantly higher platelet levels at the nadir than either vehicle controls, or mice treated with G-CSF ( Table 2 ). The combination of TPO plus G-CSF did not significantly reduce the time needed for recovery to 50% of baseline platelet counts when compared with TPO treatment alone. However, rebound thrombocytosis was increased from 2 fold in the TPO treated mice to 3.5-fold in the TPO plus G-CSF treated mice. There was no significant difference in nadir platelet counts between TPO and TPO plus G-CSF treated mice (Fig 1B) .
Mice treated with TPO or G-CSF or TPO plus G-CSF had only a modest reduction in RBC counts compared to controls. Treatment with TPO, or TPO plus G-CSF resulted in significantly higher RBC counts at the nadir (Table 2 ). In TPO andor G-CSF treated mice, FU3C counts reached nadir Day levels on day 13 and FU3C counts recovered to near baseline levels by day 20 (Fig 1C) . This was associated with an earlier increase in PB reticulocytes in the treated mice. Recovery of the reticulocyte index started on day 6 compared to day (Fig 1D) . Mean recovery of reticulocytes to 100% of baseline was 18 days in the vehicle controls and 8 to 9 days in mice treated with TPO and/or G-CSF (Table 1) . Irradiatiodcarboplatin treatment did not affect the health of the mice and there was no mortality in any of the groups. Mice showed normal grooming behavior and were active. Mean body weights in myelosuppressed mice were slightly decreased (3% to 5%) on day 6 compared to baseline and returned to baseline by day 9. Mice which were necropsied at intermediate time points or at the end of the study showed no evidence of hemorrhage or other gross pathologic lesions.
To determine the effect of TPO, G-CSF or TPO plus G-CSF on BM recovery, myelosuppressed mice were sacrificed on days 9 and 13. BM cellularity and the percentage of neutrophils were higher in the TPO, G-CSF, or TPO plus G-CSF treated mice compared to vehicle controls, except on day 13, when TPO treatment did not result in a statistically significant increase in neutrophils (Fig 2A and B) . On both days, megakaryocyte counts/mm2 were significantly increased in the sternal BM of TPO or TPO plus G-CSF treated mice compated to vehicle controls (Fig 2C) . TPO treatment of myelosuppressed mice significantly enhanced the number of CFU-GM present in femoral BM in mice killed on day 9 (Fig 3A) . G-CSF treatment increased the number of CFU-GM colonies compared to vehicle treated mice, although this was not statistically significant. The combination of TPO plus G-CSF did not result in CFU-GM colony numbers above those for mice treated with TPO EfSect of TPO and G-CSF on BM recovely.
Effect of TPO and G-CSF on progenitor cells.
For alone. However, when mice were sacrificed on day 13, TPO plus G-CSF treatment appeared to exert additive effects on recovery of CFU-GM, compared to vehicle controls, or TPO or G-CSF alone. The results for BFU-E and CFU-GEMM are qualitatively similar to those for CFU-GM, and are depicted in Fig 3B and C .
As it was difficult to discern CFU-Meg from mixed colonies when TPO, SCF, and GM-CSF were all present, additional plates were done in the presence of TPO alone to evaluate the effects of in vivo TPO, G-CSF, and TF' O plus G-CSF treatment on TPO-responsive CFU-Meg. On day 9, TPO or G-CSF alone and TPO plus G-CSF enhanced the The results for splenic progenitors were similar to those obtained from the BM, and are displayed in Table 3 . TPO plus G-CSF treatment significantly increased splenic CFU-GM, CFU-GEMM, and BFU-E above vehicle controls on day 9. By day 13, TPO and TPO plus G-CSF both enhanced CFU-GM, CFU-GEMM, and BFU-E compared to vehicle controls. On both days, the combination of TPO plus G-CSF had an additive effect on CFU-GM, CFU-GEMM, and BFU-E compared to treatment with G-CSF or TPO alone.
DISCUSSION
Several cytokines have been shown to accelerate hematopoietic recovery after myelosuppression*""'; G-CSF is one of the most effective of these factors. In several studies G-CSF has been shown to act either in an additive or synergistic fashion with other cytokines to increase the number of BM progenitors, and/or peripheral platelet or neutrophil Myelosuppressed mice were treated with vehicle, TPO (90 pg/kg) and/or G-CSF (250 pg/kg) for 8 or 12 days. Spleens were harvested 24 t Single cell suspensions from spleens were plated in 0.3% agar with rTP0 (750 U/mL) and GM-CSF (100 U/mL) and colonies (clusters of >40 * Single cell suspensions from spleens were plated in 3% methyl cellulose with EPO (2 U/mL), SCF (10 ng/mL) and GM-CSF (100 UlmL) and 9 Significant differences between TPO or TPO plus G-CSF treatment and vehicle ( P < .01).
hours later and processed as described in Materials and Methods. Values represent mean colonies per plate + SD (n = 5).
cells) were counted 6 days later.
colonies were counted 14 days later.
For personal use only. on October 22, 2017. by guest www.bloodjournal.org From CoUnts.23,32-36 Data obtained in the present study confirms previous observations that either G-CSF or TPO alone can accelerate hematopoietic progenitor and PB recovery in myelosuppressed mice and shows that the combination of both factors can reduce the duration of neutropenia compared to each factor used alone.
TPO treatment of myelosuppressed mice resulted in shorter platelet recovery times as shown previously by our laboratory and other^.'^.^^.^^ In addition, earlier recovery of megakaryocytes in the BM, and shortened times to neutrophil, platelet, and RBC recovery were ob~erved.'~ Our results are also consistent with several recently reported studies demonstrating an effect of TPO on hematopoietic lineages other then platelets. In myelosuppressed dogs, rats, and primates, the duration of neutropenia was reduced by the TPO t~eatment.~.~' In a less severe myeloablation model in primates, TPO treatment also had a beneficial effect on red blood cell recovery.43 Because CFU-GM are significantly increased in mice treated with TPO, the improved recovery of platelets and neutrophils in myelosuppressed animals is most likely related to the effect of TPO on progenitor cells (this study andi4.I5).
In this study, G-CSF, like TPO, exerted multilineage effects. G-CSF treatment enhanced platelet, reticulocyte and neutrophil recovery in the PB as well as CFU-Meg and CFU-GM in the BM. BM cellularity was also higher in the G-CSF treated mice compared to controls on day 9. Other investigators have also demonstrated multilineage effects of G-CSF. Patchen et aIz3 and Tanikawa et a133 have shown that G-CSF treatment expedites RBC, platelet, and white blood cell (WBC) recovery in irradiated mice. Previous work has also shown that G-CSF can affect primitive hematopoietic cells (blast cell colony forming cells) to accelerate their entry into cell cycle.u Thus, as speculated for TPO, it is possible that G-CSF exerts its effects on platelet and reticulocyte recovery by increasing the numbers of progenitor cells able to respond to the appropriate differentiation factors (eg, TPO and EPO, respectively). It is also possible, of course, that indirect effects of G-CSF play a role, such as increasing responsiveness to interleukin-1 (IL-l), mediated by a G-CSF-induced increase in IL-1 receptor expre~sion.~'
In addition to their individual effects, TPO and G-CSF in combination shortened the time to neutrophil recovery in myelosuppressed mice, compared to vehicle and both TPO and G-CSF treatment alone. We used doses of recombinant human G-CSF and TPO which would give near maximal responses to be able to determine possible negative interactions. '7,46 A similar synergistic effect on neutrophils and/or WBC counts was recently reported in mice treated with high doses of TPO plus G-CSF following BM tran~plantation;~ and in a model with more severe myelosuppression than in this study." Similar results were recently obtained in myelosuppressed nonhuman primates that were treated with lower doses of G-CSF and pegylated megakaryocyte growth and development factor (rMGDF).48 These results with lower doses indicate that the faster recovery of neutrophils after TPO and G-CSF treatment is not dependent on high concentrations of TPO or G-CSF.
Combined treatment with TPO plus G-CSF does not always improve neutrophil recovery over that seen with individual factors. Akahori et a14' reported that when mice were myelosuppressed with Mitomycin C and treated with either TPO, G-CSF, or TPO plus G-CSF for 9 or 13 days, the combination of G-CSF and TPO did not further improve neutrophil recovery compared to G-CSF treatment alone. Similarly, when the combined treatment of TPO and G-CSF was given for 21 days to nonhuman primates after myeloablation with hepsulfan, neutrophil recovery a150 was the same as with G-CSF alone.49 These results suggest that there might be differences in neutrophil recovery depending on the type and degree of myelosuppression induced. In addition, the doses of TPO (5 ygkg of native TPO in the mouse study and 2.5 pgkg pegylated TPO in the monkey study) and G-CSF (10 pg/kg/d) used were low in both studies. Higher doses of TPO and G-CSF might be necessary to see a synergistic effect on neutrophil recovery in these models. Treatment with TPO plus G-CSF did not shorten the duration of thrombocytopenia in myelosuppressed mice compared to TPO alone. Although there was a higher rebound thrombocytosis in mice treated with the combination of G-CSF and TPO, this was not accompanied by increased numbers of CFU-Meg. Additionally, the number of megakaryocytes in the BM was similar in the TPO plus G-CSF treated mice compared to the mice treated with TPO alone. One possible explanation for this is that the maturation time for platelets is fixed, and cannot be shortened further. Previous experiments using higher doses of TPO or different dosing regimens support this hypothesis'' (unpublished results, September 1995). Similar results were recently published in myelosuppressed non-human primates which were treated with pegylated rMGDF and G-CSF or with pegylated rMGDF Although combined treatment with TPO plus G-CSF did result in an additive effect on the number of BFU-E, this did not translate into increased numbers of reticulocytes or RBCs compared to mice treated with TPO or G-CSF alone. Other studies in which animals have been treated with a combination of TPO plus G-CSF also found no difference in effect on RBC recovery with combined treatment compared to TPO treatment a l~n e .~' .~"
The combination of TPO plus G-CSF did not result in any negative effects on platelet or red blood cell recovery compared to TPO treatment alone, suggesting that precursors of all lineages expanded and matured. Similar results were reported by Hokom et a139 when mice were treated with lower doses of TPO plus murine G-CSF and by Farese et in radiation induced myelosuppressed non-human primates treated with pegylated rMGDF and G-CSF. This is in contrast to another study of nonhuman primates that were treated with hepsulfan. These animals had suppressed platelet recovery when they were treated with TPO plus G-CSF for 21 days.49 The delayed platelet recovery was related to the dosing regimen of TPO and G-CSF. When the animals were treated for 1 week with TPO followed by 2 weeks of TPO plus G-CSF, the fall in platelet counts was prevented and time of neutropenia was still shortened.
The results from our study show that administration of
For personal use only. on October 22, 2017. by guest www.bloodjournal.org From TPO plus G-CSF to myelosuppressed mice enhanced the regeneration of CFW-GM, CFU-GEMM, BFU-E, and CFUMeg. The combination of cytokines also increased total BM cellularity as well as the numbers of neutrophils and megakaryocytes in BM. Consequently, combined G-CSF and TPO therapy shortened the time to recovery of platelets, red blood cells and neutrophils in PB. Alone, P O treatment was more effective in preventing the decrease in neutrophil, platelet, and RBC counts in this model than G-CSF. TPO plus G-CSF administration synergistically reduced the seventy and duration of neutropenia compared to administration of G-CSF or TPO alone. However, there was no additional reduction in thrombocytopenia or anemia compared to TPO treatment alone. Clinical trials will establish whether comparable effects can be obtained in humans with thrombocytopenia, anemia, andlor neutropenia associated with myelosuppression and BM transplantation.
